171 related articles for article (PubMed ID: 25182712)
1. Distribution and antimicrobial susceptibility profile of extended-spectrum β-lactamase-producing Proteus mirabilis strains recently isolated in Japan.
Kanayama A; Kobayashi I; Shibuya K
Int J Antimicrob Agents; 2015 Feb; 45(2):113-8. PubMed ID: 25182712
[TBL] [Abstract][Full Text] [Related]
2. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
[TBL] [Abstract][Full Text] [Related]
4. Regional Spread of CTX-M-2-Producing Proteus mirabilis with the Identical Genetic Structure in Japan.
Kato K; Matsumura Y; Yamamoto M; Nagao M; Takakura S; Ichiyama S
Microb Drug Resist; 2017 Jul; 23(5):590-595. PubMed ID: 27834610
[TBL] [Abstract][Full Text] [Related]
5. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.
Nakano R; Nakano A; Abe M; Inoue M; Okamoto R
J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848
[TBL] [Abstract][Full Text] [Related]
6. CTX-M-1 extended-spectrum beta-lactamase-producing Proteus mirabilis in Greece.
Karapavlidou P; Sofianou D; Manolis EN; Pournaras S; Tsakris A
Microb Drug Resist; 2005; 11(4):351-4. PubMed ID: 16359194
[TBL] [Abstract][Full Text] [Related]
7. Occurrence and molecular analysis of extended-spectrum {beta}-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002.
Ho PL; Ho AY; Chow KH; Wong RC; Duan RS; Ho WL; Mak GC; Tsang KW; Yam WC; Yuen KY
J Antimicrob Chemother; 2005 Jun; 55(6):840-5. PubMed ID: 15857942
[TBL] [Abstract][Full Text] [Related]
8. Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, β-lactamase distribution, phylogroups, and co-resistance.
Hansen DS; Schumacher H; Hansen F; Stegger M; Hertz FB; Schønning K; Justesen US; Frimodt-Møller N;
Scand J Infect Dis; 2012 Mar; 44(3):174-81. PubMed ID: 22364227
[TBL] [Abstract][Full Text] [Related]
9. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and resistance patterns of extended-spectrum and AmpC β-lactamase in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella serovar Stanley in a Korean tertiary hospital.
Park SD; Uh Y; Lee G; Lim K; Kim JB; Jeong SH
APMIS; 2010 Oct; 118(10):801-8. PubMed ID: 20854475
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
[TBL] [Abstract][Full Text] [Related]
12. A binational cohort study of intestinal colonization with extended-spectrum β-lactamase-producing Proteus mirabilis in patients admitted to rehabilitation centres.
Adler A; Baraniak A; Izdebski R; Fiett J; Gniadkowski M; Hryniewicz W; Salvia A; Rossini A; Goossens H; Malhotra S; Lerman Y; Elenbogen M; Carmeli Y;
Clin Microbiol Infect; 2013 Feb; 19(2):E51-8. PubMed ID: 23210906
[TBL] [Abstract][Full Text] [Related]
13. [Characteristic of fluoroquinolone resistant clinical isolates of K. pneumoniae, P. mirabilis and E. coli producing ESBL and AmpC beta-lactamases].
Rzeczkowska M; Piekarska K; Gierczyński R
Med Dosw Mikrobiol; 2012; 64(4):285-95. PubMed ID: 23484420
[TBL] [Abstract][Full Text] [Related]
14. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
[TBL] [Abstract][Full Text] [Related]
15. Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005--the new 'MRSAs'?
Damjanova I; Tóth A; Pászti J; Hajbel-Vékony G; Jakab M; Berta J; Milch H; Füzi M
J Antimicrob Chemother; 2008 Nov; 62(5):978-85. PubMed ID: 18667450
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of extended-spectrum beta-lactamases in Proteus mirabilis in a Taiwanese university hospital, 1999 to 2005: identification of a novel CTX-M enzyme (CTX-M-66).
Wu JJ; Chen HM; Ko WC; Wu HM; Tsai SH; Yan JJ
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):169-75. PubMed ID: 17913434
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis.
Kurihara Y; Hitomi S; Oishi T; Kondo T; Ebihara T; Funayama Y; Kawakami Y
J Infect Chemother; 2013 Oct; 19(5):799-805. PubMed ID: 23371453
[TBL] [Abstract][Full Text] [Related]
18. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
[TBL] [Abstract][Full Text] [Related]
19. [Detection of bla(CTX-M) beta-lactamase genes in extended-spectrum beta-lactamase producing gram-negative bacteria].
Bayraktar B; Toksoy B; Bulut E
Mikrobiyol Bul; 2010 Apr; 44(2):187-96. PubMed ID: 20549952
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial Susceptibility and Molecular Epidemiology of
Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY
Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
